26,120 Shares in Zoetis Inc. $ZTS Purchased by Jones Financial Companies Lllp

Jones Financial Companies Lllp acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 26,120 shares of the company’s stock, valued at approximately $1,877,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. RFG Advisory LLC lifted its holdings in shares of Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares during the last quarter. Financial Engines Advisors L.L.C. increased its position in Zoetis by 4.4% during the 3rd quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after buying an additional 87 shares in the last quarter. Physician Wealth Advisors Inc. increased its position in Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock valued at $73,000 after buying an additional 91 shares in the last quarter. Smithfield Trust Co raised its stake in Zoetis by 4.2% during the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after buying an additional 92 shares during the last quarter. Finally, Howland Capital Management LLC raised its stake in Zoetis by 4.5% during the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after buying an additional 92 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. cut their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Citigroup lowered their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Piper Sandler dropped their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating on the stock in a research note on Monday, August 10th. UBS Group cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Finally, Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $109.23.

Zoetis Stock Down 0.8%

Shares of Zoetis stock opened at $77.13 on Tuesday. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $157.21. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The company’s 50 day moving average is $75.70 and its 200 day moving average is $96.81. The company has a market cap of $31.87 billion, a price-to-earnings ratio of 12.71, a price-to-earnings-growth ratio of 1.82 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Research analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.